National and Kapodistrian University of Athens
Μελέτη της παθογενετικής δράσης αυτοαντισωμάτων σε νόσους του κεντρικού νευρικού συστήματος
Abstract
dc:descriptionVarious research studies over the past few years have solidified the view that a growing group of neurological disorders are mediated by autoantibodies against membrane and intracellular proteins of the central nervous system (CNS). Indeed, an increasing number of patients are diagnosed with autoimmune CNS disorders which previously were considered to be idiopathic or even psychiatric. In the present study, we focused on a group of rare autoimmune disorders of the CNS, namely Stiff Person Syndrome (SPS), cerebellar ataxia and limbic encephalitis.Groups of patients suffering from these disorders harbor high titers of antibodies against γ-aminobutyric decarboxylase (GAD65). This enzyme catalyzes the decarboxylation of L-glutamic to γ-aminobutyric acid (GABA), the most common inhibitory neurotransmitter of the brain. Low titers of these autoantibodies are also found in diabetes type I. It is still unclear whether anti-GAD65 antibodies are pathogenic or markers of these disorders. Do they have different epitope specificities through which they manifest a distinct role among different clinical diseases? And if they are diagnostic markers, are there autoantigens that haven’t been identified yet? To address these questions, we used a luminescence immunoprecipitation system (LIPS), in order to determine the major GAD65 epitopes that are recognized in these disorders. We used 9 GAD-positive patients with concurrence of either cerebellar ataxia or downbeat nystagmus or stiff limp, 8 GAD-positive patients with concurrence of epilepsy and 4 patients with autoimmune encephalitis and autoimmune epilepsy. 6 SPS patients were used as positive controls. All patient sera were also screened for new autoantibodies by means of live staining in primary hippocampal neurons.In addition, we screened patients with cerebellar ataxia and SPS for new autoantibodies using live staining in primary hippocampal neurons and sera immunoprecipitations. 85 patients with cerebellum signs and 5 patients with anti-GAD65 antibodies and cerebellar ataxia were screened. To identify new autoantibodies in SPS, we used 66 sera with high titers of anti-GAD65 antibodies.Our results demonstrated that all patient sera recognized the same epitopes of the GAD65 enzyme, which support the view that anti-GAD antibodies may not be pathogenic. We also found three patients with epilepsy may harbor new autoantigens. Although we have not yet identified these antibodies nor did we identify any in the SPS syndrome, we recognized antibodies against 1,4,5-triposphate inositol receptor I (IP3R1) in patients with cerebellar ataxia. It should be noticed, that for the first time these antibodies were found in patients with co-morbidities such as multiple sclerosis (1 patient) and an underlying neurodegenerative disorder (2 patients). It should be interesting in the future to screen more patients with neurodegenerative disorders in order to unravel the role of anti-IP3R1 antibodies.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Fouka, Pinelopi
- Φούκα, Πηνελόπη
Subjects
dc:subject × 10Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41626